Skip to main content
Premium Trial:

Request an Annual Quote

Bruker s Q3 Receipts Grow 6.3 Percent as Firm Posts Profit; Daltonics, AXS Post Revenue Gains

NEW YORK, Nov. 3 (GenomeWeb News) - Bruker BioSciences yesterday posted a profit in the third quarter as revenues increased 6.3 percent and R&D spending fell slightly.


Total receipts for the three months ended Sept. 30 increased to $70.7 million from $66.5 million year over year.   Revenue from products increased 4.4 percent to $61 million in the quarter, service receipts improved 1.7 percent in the quarter to $8.7 million, and other revenues jumped 46 percent to $928,000, the company said.


Bruker said that third quarter revenues from its Daltonics division jumped 7.8 percent year over year to $36.9 million, while receipts for its AXS business increased 4.9 percent to $33.9 million.


Third-quarter R&D spending declined to just under $10 million from $10.8 million in the year-ago period.


Bruker also posted a net profit of $1 million, or $.01 per share, from a net loss of $3 million, or $.03 per share, in last year's third quarter.


Bruker said it had around $95.3 million in cash and short-term investments as of Sept. 30.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.